Oncology Institute, Inc. (TOI)
NASDAQ:TOI
Want to see TOI full AI Analyst Report?
TOI Stock Chart & Stats
$3.85
-$0.01(-3.73%)
At close: 4:00 PM EST
$3.85
-$0.01(-3.73%)
Day’s Range― - ―
52-Week Range$2.02 - $4.88
Previous CloseN/A
Volume198.36K
Average Volume (3M)2.12M
Market Cap
$323.20M
Enterprise Value$315.93M
Total Cash (Recent Filing)$33.56M
Total Debt (Recent Filing)$26.29M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
May 13, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding98,839,140
10 Day Avg. Volume1,511,911
30 Day Avg. Volume2,116,708
Financial Highlights & Ratios
PEG Ratio2.27
Price to Book (P/B)-209.23
Price to Sales (P/S)6.54
P/FCF Ratio-118.37
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue0.63
Enterprise Value/Gross Profit4.55
Enterprise Value/Ebitda-10.84
Forecast
1Y Price Target
$7.00Price Target Upside81.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$647.82M
Bulls Say, Bears Say
Bulls Say
Delegated Contracts GrowthFaster-than-anticipated ramp of delegated contracts and accelerated pharmacy expansion could lift revenue visibility and support higher margins as managed care volumes increase.
Pharmacy Business DiversificationPharmacy operations act as a natural hedge against fluctuations in patient utilization, helping stabilize revenue and protect margins when other services vary.
Technology And EfficiencyArtificial intelligence initiatives are expected to boost operating efficiency and drive margin improvement by reducing costs and streamlining workflows.
Bears Say
Market Sentiment And Valuation DisconnectShare underperformance despite reaffirmed guidance may signal investor skepticism about future execution, keeping valuation multiples pressured until results prove out.
Patient Services Performance RiskA cautious outlook for the patient services segment suggests persistent execution or demand challenges that could limit overall revenue growth despite gains elsewhere.
Oncology Institute News
TOI FAQ
What was Oncology Institute, Inc.’s price range in the past 12 months?
Oncology Institute, Inc. lowest stock price was $2.02 and its highest was $4.88 in the past 12 months.
What is Oncology Institute, Inc.’s market cap?
Oncology Institute, Inc.’s market cap is $323.20M.
When is Oncology Institute, Inc.’s upcoming earnings report date?
Oncology Institute, Inc.’s upcoming earnings report date is May 13, 2026 which is in 19 days.
How were Oncology Institute, Inc.’s earnings last quarter?
Oncology Institute, Inc. released its earnings results on Mar 12, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.03.
Is Oncology Institute, Inc. overvalued?
According to Wall Street analysts Oncology Institute, Inc.’s price is currently Undervalued.
Does Oncology Institute, Inc. pay dividends?
Oncology Institute, Inc. does not currently pay dividends.
What is Oncology Institute, Inc.’s EPS estimate?
Oncology Institute, Inc.’s EPS estimate is -0.08.
How many shares outstanding does Oncology Institute, Inc. have?
Oncology Institute, Inc. has 98,839,140 shares outstanding.
What happened to Oncology Institute, Inc.’s price movement after its last earnings report?
Oncology Institute, Inc. reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went up 8.397%.
Which hedge fund is a major shareholder of Oncology Institute, Inc.?
Currently, no hedge funds are holding shares in TOI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncology Institute Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (81.82% Upside)
$7.00 (81.82% Upside)
Blogger Sentiment
Bullish
TOI Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 91.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
63.88%
12-Months-Change
Fundamentals
Return on Equity
759.71%
Trailing 12-Months
Asset Growth
-5.21%
Trailing 12-Months
Company Description
Oncology Institute, Inc.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
TOI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful operational and financial progress—record revenue, large pharmacy growth, expanded capitated relationships, improved margins, first positive adjusted EBITDA quarter, and strengthened balance sheet and leadership. Key near-term headwinds include seasonal Q1 weakness, reliance on pharmacy/dispensing, transitional MLR pressure during delegated ramps, and a free-cash-flow range that allows for interim negative cash flow. Overall, positives (strong top-line growth, margin improvement, profitability milestone, and clear 2026 guidance) significantly outweigh the manageable short-term risks.View all TOI earnings summariesTOI Stock 12 Month Forecast
Average Price Target
$7.00
▲(81.82% Upside)
Technical Analysis
Ownership Overview
24.58% Insiders
6.93% Mutual Funds
0.08% Other Institutional Investors
61.09% Public Companies and
Individual Investors